hrp0084fc8.6 | Obesity - Basic | ESPE2015

Metabolic Effects of ADP355, Protein-Based Adiponectin Receptor Agonist, on Mice with High-Fat Diet Induced Fatty Liver Disease

Lee Eun Byoul , Kim Tae Hyuk , Lee Woo Jung , Kwon Ah Reum , Chae Hyun Wook , Kim Duk Hee , Kim Ho-Seong

Background: Adiponetin is considered a protective hormone exhibiting beneficial effects against insulin resistance, cardiovascular disease, and cancer. Non-alcoholic fatty liver disease (NAFLD) is considered the hepatic component of insulin resistance. Pharmacological activation of adiponectin signaling might be helpful for treatment of NAFLD, but it is difficult to develop the whole adiponectin protein as a drug because the C-terminal globular domain of adiponectin is extreme...

hrp0095fc2.4 | Bone, Growth Plate and Mineral Metabolism | ESPE2022

Patient-reported outcomes from a randomized open-label phase 3 trial comparing burosumab vs conventional therapy in children with X-linked hypophosphatemia: results from the 24-week treatment extension period

Padidela Raja , Whyte Michael P , Glorieux Francis H , Munns Craig F , Ward Leanne M , Nilsson Ola , Portale Anthony A , Simmons Jill H , Namba Noriyuki , Cheong Hae Il , Pitukcheewanont Pisit , Sochett Etienne , Högler Wolfgang , Muroya Koji , Tanaka Hiroyuki , Gottesman Gary S , Biggin Andrew , Perwad Farzana , Williams Angela , Nixon Annabel , Sun Wei , Chen Angel , Skrinar Alison , Imel Erik A

In a randomized open-label phase 3 trial in 62 children (1–12 years) with X-linked hypophosphatemia (XLH) (NCT 02915705), switching from conventional therapy (oral phosphate plus active vitamin D) to burosumab, a monoclonal antibody targeting fibroblast growth factor 23, significantly improved serum phosphate concentration, rickets, lower-extremity deformities, growth, mobility, and patient-reported outcomes (PROs) at 64 weeks. Children in Europe, USA, Canada, and Australia wh...

hrp0095p1-108 | Growth and Syndromes | ESPE2022

Efficacy, Observer-Reported Outcomes, and Safety of Once-Weekly Somapacitan in Children with Growth Hormone Deficiency (GHD): 4-Year Results from the REAL 3 Trial

Sävendahl Lars , Battelino Tadej , Højby Rasmussen Michael , Brod Meryl , Wai Lee Kai , Saenger Paul , Horikawa Reiko

Children with GHD are currently treated with daily subcutaneous growth hormone (GH) injections, which can be burdensome. Somapacitan is a long-acting GH derivative in development for once-weekly use in children with GHD. REAL 3 (NCT02616562) is a phase 2, multinational, randomised, open label, controlled trial assessing efficacy and safety of somapacitan vs daily GH (Norditropin®). Prepubertal, GH-naïve children with GHD received 0.04 (n=16), 0.08 (n</e...

hrp0092p1-101 | Pituitary, Neuroendocrinology and Puberty | ESPE2019

Identification of Novel Mutations in FGFR1 and Functional Characteristics in Patients with Isolated Gonadotropin-Releasing Hormone Deficiency

Lee Yena , Huh Juyoung , Oh Arum , Kim Gu-Hwan , Yoo Han-Wook , Choi Jin-Ho

Background: Isolated gonadotropin-releasing hormone (GnRH) deficiency (IGD) is caused by a deficiency in GnRH production, secretion or action and a highly heterogeneous disorder with wide phenotypic spectrum including Kallmann syndrome (KS) with anosmia and normosmic idiopathic hypogonadotropic hypogonadism (nIHH). More than 30 different causative genes have been identified in several studies. FGFR1 mutations have been identified in about 3–10&#3...

hrp0092p1-216 | GH and IGFs (1) | ESPE2019

Birth Anthropometry with Cord Blood Insulin-Like Growth Factor 1 and Leptin in Korean Appropriate-For-Gestational-Age Infants Born at ≥28 Weeks' Gestation

Kang Seok Jin , Kim Se Jin , Lee Ga Hyun , Kim Heung Sik

Background: We investigated the relationship of birth anthropometry with cord blood insulin-like growth factor 1 (IGF-1) and leptin levels in Korean infants born at ≥28 weeks' gestation.Methods: One hundred five appropriate-for-gestational-age (AGA) infants, defined as infants with birth weights (BWs) between the 10th and 90th percentiles for gestational age, were enrolled. Enrolled infants were stratified into...

hrp0092p1-217 | GH and IGFs (1) | ESPE2019

Association Between Nonalcoholic Fatty Liver Disease and Growth Hormone Deficiency in Patients with Childhood-Onset Hypopituitarism

Kim Se Jin , Kim Heung Sik , Lee Ga Hyun , Kang Seok Jin

Background & Aims: Although, there has been reports demonstrating association between adult-onset hypopituitarism and development of nonalcoholic fatty liver disease (NAFLD), studies are lacking regarding the development of NAFLD in children and young adult with childhood-onset hypopituitarism. We aimed to identify association between NAFLD and hypopituitarism in these patients.Methods: 76 Korean children and young a...

hrp0092p1-268 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology (1) | ESPE2019

Idiopathic Scoliosis in Girls with Central Precocious Puberty: Incidence and Effect of Gonadotropin-Releasing Hormone Agonists

Chung Lindsey Yoojin , Nam Hyo-Kyoung , Rhie Young-Jun , Huh Rimm , Lee Kee-Hyoung

Adolescent idiopathic scoliosis (AIS) is the most common form of scoliosis, affecting approximately 2 to 4 percent of adolescents. AIS by definition occurs in children between 10 to 18 years old, in periods of growth spurts and puberty changes. In patients with central precocious puberty (CPP), generally, growth spurts start earlier than their peers. Therefore, AIS in patients with CPP is expected to develop earlier in juvenile age. Especially in girls, both AIS and CPP are mo...

hrp0092lb-15 | Late Breaking Posters | ESPE2019

Efficacy of 3-Monthly Compare to Monthly Depot GnRH Agonist (Triptorelin Pamoate) in the Treatment of Girls with Central Precocious Puberty in Korea

Yoojin Chung Lindsey , Huh Rimm , Nam Hyo-Kyoung , Rhie Young-Jun , Lee Kee-Hyoung

Background: Triptorelin depot is largely used to treat central precocious puberty (CPP) in children and currently 3 monthly depot was introduced. No Korean data are available on 3-monthly GnRH agonist treatment in central precocious puberty.Aim: To compare the efficacy of Triptorelin 11.25mg 3-months depot with 3.75mg monthly depot in suppressing pubertal development from the beginning to 6 month and 1 year after the tre...

hrp0092p2-24 | Adrenals and HPA Axis | ESPE2019

Adult Height and Growth Pattern in Patients with Classic Congenital Adrenal Hyperplasia

Lee Ga Hyun , Kim Se Jin , Kang Seok Jin , Kim Heung Sik

Background: Congenital adrenal hyperplasia (CAH), mostly caused by 21-hydroxylase deficiency, is autosomal recessive disorder characterized by impaired cortisol synthesis. It can be presented with a combination of aldosterone and cortisol deficiency and androgen excess. Therefore, excess production of androgen and glucocorticoid replacement can result to early bone maturation and ultimately diminished adult height (AH).Objectives...

hrp0092p2-122 | Fat, Metabolism and Obesity | ESPE2019

Insulin-like Growth Factor-1 and Binding Protein-3 in Children with Metabolic Syndrome

Lee yoonji , Ahn Moonbae , Kim Seulki , Choi yujung , Cho Wonkyung , Jung Minho , Suh Byung-Kyu

Purpose: To examine the association of Insulin-like growth factor-1 (IGF-1) and binding protein-3 (IGFBP-3) with metabolic parameters of childhood obesity and assess its relationship with the presence of metabolic syndrome (MetS)Methods: A cross-sectional study of total 307 children and adolescents referred for growth assessment was performed. Subjects were divided into three groups based on body mass index (BMI) percent...